Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease

Urology

Volumn 53, Issue 1, 1999, Pages 126-130

  Carter, H Ballentine ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY;

ADULT; AGE FACTORS; AGED; HUMANS; MALE; MIDDLE AGED; PALPATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION;

EID: 0345196579     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00466-X     Document Type: Article

References (15)

1. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men establishment of age-specific reference ranges . JAMA. 270:1993;860-864.
2. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med. 335:1996;304-310.
3. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. JAMA. 277:1997;1452-1455.
4. Epstein J.I., Carmichael M., Pizov G., et al. Influence of capsular penetration on progression following radical prostatectomy a study of 196 cases with long-term follow-up . J Urol. 150:1993;135-141.
5. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
6. Epstein J.I., Partin A.W., Sauvageot J., et al. Prediction of progression following radical prostatectomy a multivariate analysis of 721 men with long-term follow-up . Am J Surg Pathol. 20:1996;286-292.
7. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
8. Carter H.B., Pearson J.D. PSA and the natural course of prostate cancer. Schroder F.H. Recent Advances in Prostate Cancer and BPH. 1997;187-193 Parthenon Publishing Group, New York.
9. Labrie F., Candas B., Cusan L., et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 47:1996;212-217.
10. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 276:1996;1309-1315.
11. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 273:1995;289-294.
12. Eddy D.M. Screening for cervical cancer. Ann Intern Med. 113:1990;214-226.
13. Alexander R.B., Maguire M.G., Epstein J.I., et al. Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol. 141:1989;880-882.
14. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374.
15. Humphrey P.A., Keetch D.W., Smith D.S., et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol. 155:1996;816-820.